{"product_id":"zimvie-pestle-analysis","title":"ZimVie PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, healthcare spending trends, and rapid medtech innovation are shaping ZimVie's trajectory—our concise PESTLE snapshot highlights key risks and opportunities you need to know; purchase the full, editable PESTLE Analysis to get detailed insights, actionable recommendations, and data-ready charts for immediate strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade Policy and Tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in international trade agreements and tariffs drive input and finished-goods costs for ZimVie; e.g., US tariffs on Chinese medical devices rose effective 2024, lifting some component import costs by 5–12%, while EU trade barriers pushed average landed costs up ~6% in 2023–24.\u003c\/p\u003e\n\u003cp\u003eWith a global supply chain, deterioration in US-China ties or new European non-tariff barriers can disrupt manufacturing lead times, contributing to reported FY2024 COGS growth of ~7% year-over-year for comparable device makers.\u003c\/p\u003e\n\u003cp\u003eStrategic planning must model tariff scenarios and diversify sourcing—shifting even 15–20% of procurement to alternate regions can stabilize margins and help retain competitive pricing across key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Reform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpgovernment-led shifts in us medicare and medicaid reimbursement toward value-based models recent proposals to expand adult dental benefits could raise access implants potentially enlarging zimvie addressable market from roughly implant sector estimate political momentum for coverage expansion policy discussions upside while european austerity pricing caps risk margin pressure where single-payer procurement dominates.\u003e\n\u003c\/pgovernment-led\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to EU MDR (fully applicable since May 2021) and global regulatory harmonization raises compliance costs for ZimVie, with industry estimates showing MDR-related conformity costs up to 5-10% of product revenues; aligning submissions across FDA and notified bodies remains a priority to avoid delays in the 20+ markets where ZimVie seeks authorization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability in Manufacturing Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical unrest in manufacturing hubs where ZimVie or key suppliers operate can cause supply chain delays; for example, global supply disruptions in 2024 raised lead times by up to 28% in some medical device supply chains.\u003c\/p\u003e\n\u003cp\u003eMonitoring emerging-market political climates is essential to mitigate expropriation, civil unrest, or abrupt labor-law changes that could affect ~15–20% of components sourced from Asia and Latin America.\u003c\/p\u003e\n\u003cp\u003eEstablishing redundant supply chains in stable regions—shifting 10–25% of sourcing to North America or EU facilities—reduces disruption risk and supports continuity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUp to 28% longer lead times reported in 2024 supply disruptions\u003c\/li\u003e\n\u003cli\u003e15–20% of components sourced from higher-risk emerging markets\u003c\/li\u003e\n\u003cli\u003e10–25% of sourcing can be shifted to stable regions to reduce risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Funding and Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernmental funding for oral health campaigns—e.g., WHO noting 3.5 billion people affected by oral diseases in 2022—increases demand for advanced restorative solutions, benefiting ZimVie’s implant and restorative product lines.\u003c\/p\u003e\n\u003cp\u003eDental association lobbying raises oral health on national agendas; countries increasing oral health budgets (US dental spending ~135 billion USD in 2023) boost procedure volumes and device uptake.\u003c\/p\u003e\n\u003cp\u003ePolitical recognition of oral-systemic links drives higher utilization rates of ZimVie products through public programs and reimbursement policies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncreased public funding → higher procedure demand\u003c\/li\u003e\n\u003cli\u003eAdvocacy elevates policy priority and reimbursement\u003c\/li\u003e\n\u003cli\u003eOral-systemic recognition raises device utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical risks, tariffs and MDR squeeze ZimVie margins—reshore 10–25% to cut disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts—tariffs (US-China 2024 +5–12%), EU pricing caps, Medicare\/Medicaid dental proposals (CMS 2024) and MDR compliance (costs ~5–10% revenue)—drive ZimVie margin and access risks; supply-chain political unrest raised lead times up to 28% in 2024; reallocating 10–25% sourcing to stable regions can cut disruption exposure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2023–24 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff impact\u003c\/td\u003e\n\u003ctd\u003e+5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMDR compliance\u003c\/td\u003e\n\u003ctd\u003e5–10% rev.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time rise\u003c\/td\u003e\n\u003ctd\u003eUp to 28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSourcing shift\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect ZimVie across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses ZimVie’s full PESTLE into a shareable, slide-ready summary that highlights key external risks and market drivers for quick alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Discretionary Spending Levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-end dental procedures like implants and complex restorations are largely paid out-of-pocket and therefore closely tied to disposable income; U.S. consumer spending fell 0.2% in Q4 2025 vs Q3 2025 amid 3.4% inflation, pressuring elective demand. Economic downturns prompt patients to defer elective surgeries in favor of essential care—global elective procedure volumes dropped ~6% in 2024 vs 2019. ZimVie's revenue growth remains correlated with global GDP and middle-class financial confidence, with middle-income households accounting for roughly 60% of elective dental spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrevailing interest rates affect ZimVie’s customers—dental practices and DSOs—by raising borrowing costs for expensive equipment and inventory; US prime rate rose to 8.50% in 2024, tightening financing for capex-heavy purchases.\u003c\/p\u003e\n\u003cp\u003eHigher rates can slow clinic expansion, reducing demand for ZimVie’s digital dentistry tools and implants; US dental capex growth decelerated to ~2% in 2024 vs 6% in 2022.\u003c\/p\u003e\n\u003cp\u003eInvestors track central bank policy—Fed pauses or cuts could revive provider capex cycles, while further hikes would suppress investment in new tech and consolidation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForeign Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a multinational MedTech firm, ZimVie faces currency translation risk that trimmed adjusted EBITDA by an estimated 2–3% in FY2024 as the US dollar strengthened ~8% vs the euro, pressuring reported earnings and margins.\u003c\/p\u003e\n\u003cp\u003eA stronger dollar makes ZimVie products pricier abroad, risking share losses to local competitors in Europe and emerging markets where price elasticity is high.\u003c\/p\u003e\n\u003cp\u003eZimVie uses forward contracts and option hedges—hedged exposures covered roughly 60% of near-term FX risk in 2024—and is expanding localized manufacturing to lower currency pass-through and protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising costs for medical-grade titanium (+18% YoY in 2024) and specialty polymers, plus a 22% surge in industrial energy prices in key markets, are increasing ZimVie’s COGS for dental implants and restorative products.\u003c\/p\u003e\n\u003cp\u003eZimVie must weigh passing costs via price hikes against volume loss to lower-cost competitors; sensitivity models show a 3–5% price rise could cut volumes 4–7%.\u003c\/p\u003e\n\u003cp\u003eActive monitoring of global commodity indices (titanium, polymer resin, energy) is required to protect gross margins near the 60% target reported in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTi prices +18% (2024)\u003c\/li\u003e\n\u003cli\u003eEnergy +22% (2024)\u003c\/li\u003e\n\u003cli\u003ePrice hike elasticity: −4 to −7% volume per 3–5% increase\u003c\/li\u003e\n\u003cli\u003eTarget gross margin ~60% (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Dental Service Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsolidation of dental practices into DSOs shifts purchasing power toward large buyers; as of 2024 DSOs account for roughly 30–40% of US dental care revenue, enabling them to secure double-digit discounts on implants and biomaterials and pressuring ZimVie's margin and pricing strategy.\u003c\/p\u003e\n\u003cp\u003eTransitioning to a B2B model focused on institutional contracts is vital—ZimVie must offer volume pricing, supply-chain integration, and service-level agreements to retain share as DSOs expand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 DSOs ~30–40% of US dental revenue\u003c\/li\u003e\n\u003cli\u003eDSO-negotiated discounts often 10–20% on implants\u003c\/li\u003e\n\u003cli\u003eZimVie needs B2B pricing, logistics, contract support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElective dental hit by weaker consumer spend, rising rates and input-cost squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic sensitivity: elective dental demand tied to disposable income—US consumer spending fell 0.2% Q4 2025; global elective volumes −6% (2024 vs 2019). Higher rates (US prime 8.50% in 2024) and rising input costs (titanium +18%, energy +22% in 2024) pressure capex, margins (gross ~60% FY2024) and pricing vs DSOs (30–40% US revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElective volumes\u003c\/td\u003e\n\u003ctd\u003e−6% (2024 vs 2019)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS prime\u003c\/td\u003e\n\u003ctd\u003e8.50% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitanium\u003c\/td\u003e\n\u003ctd\u003e+18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003e+22% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~60% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDSO share\u003c\/td\u003e\n\u003ctd\u003e30–40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eZimVie PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact ZimVie PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategy or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751921594745,"sku":"zimvie-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zimvie-pestle-analysis.png?v=1772236180","url":"https:\/\/growthsharematrix.com\/products\/zimvie-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}